Interleukin-6: a promising target for the treatment of polymyalgia rheumatica or giant cell arteritis?
暂无分享,去创建一个
[1] M. Dougados,et al. Tocilizumab in Giant Cell Arteritis: A Multicenter Retrospective Study of 34 Patients , 2016, The Journal of Rheumatology.
[2] S. Reichenbach,et al. Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial , 2016, The Lancet.
[3] F. Galateau-Sallé,et al. Management of giant cell arteritis: Recommendations of the French Study Group for Large Vessel Vasculitis (GEFA). , 2016, La Revue de medecine interne.
[4] A. Saraux,et al. Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: a prospective longitudinal study , 2016, Annals of the rheumatic diseases.
[5] Antoine Martin,et al. Rapid and Sustained Response to Tocilizumab in Patients with Polymyalgia Rheumatica Resistant or Intolerant to Glucocorticoids: A Multicenter Open-label Study , 2016, The Journal of Rheumatology.
[6] B. Dasgupta,et al. Long-term efficacy and safety of tocilizumab in giant cell arteritis and large vessel vasculitis , 2016, RMD Open.
[7] T. Takeuchi,et al. Tocilizumab is effective against polymyalgia rheumatica: experience in 13 intractable cases , 2015, RMD Open.
[8] K. Barraclough,et al. 2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative , 2015, Annals of the rheumatic diseases.
[9] M. González-Gay,et al. Tocilizumab in giant cell arteritis: Multicenter open-label study of 22 patients. , 2015, Seminars in arthritis and rheumatism.
[10] G. Rossi,et al. Inflamed Temporal Artery: Histologic Findings in 354 Biopsies, With Clinical Correlations , 2014, The American journal of surgical pathology.
[11] S. Mori,et al. Glucocorticoid-resistant polymyalgia rheumatica: pretreatment characteristics and tocilizumab therapy , 2014, Clinical Rheumatology.
[12] C. Salvarani,et al. Update on polymyalgia rheumatica. , 2013, European journal of internal medicine.
[13] C. Salvarani,et al. Tocilizumab for polymyalgia rheumatica: report of two cases and review of the literature. , 2013, Seminars in arthritis and rheumatism.
[14] S. Unizony,et al. Tocilizumab for the treatment of large‐vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica , 2012, Arthritis care & research.
[15] B. Bonnotte,et al. Th1 and Th17 lymphocytes expressing CD161 are implicated in giant cell arteritis and polymyalgia rheumatica pathogenesis. , 2012, Arthritis and rheumatism.
[16] J. Besancenot,et al. Efficacy of tocilizumab in refractory giant cell arteritis. , 2012, Joint, bone, spine : revue du rhumatisme.
[17] A. Iagnocco,et al. 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative , 2012, Annals of the rheumatic diseases.
[18] Shaifali Jain,et al. Successful use of tocilizumab in polymyalgic onset biopsy positive GCA with large vessel involvement , 2011, BMJ Case Reports.
[19] J. Zwerina,et al. Anti-interleukin 6 receptor therapy as rescue treatment for giant cell arteritis , 2011, Annals of the rheumatic diseases.
[20] S. Reichenbach,et al. Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series. , 2011, Swiss medical weekly.
[21] D A Bloch,et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. , 2010, Arthritis and rheumatism.
[22] K. Hagihara,et al. Tocilizumab Ameliorates Clinical Symptoms in Polymyalgia Rheumatica , 2010, The Journal of Rheumatology.
[23] M. López-Hoyos,et al. Giant cell arteritis and polymyalgia rheumatica: role of cytokines in the pathogenesis and implications for treatment. , 2008, Cytokine.
[24] P. Merkel,et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. , 2007, Arthritis and rheumatism.
[25] L. Mortelmans,et al. Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients. , 2006, Arthritis and rheumatism.
[26] L. Cimino,et al. Interleukin-6 promoter polymorphism at position -174 in giant cell arteritis. , 2005, The Journal of rheumatology.
[27] H. Rubin,et al. Domains of health-related quality of life important to patients with giant cell arteritis. , 2003, Arthritis and rheumatism.
[28] S. Gabriel,et al. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. , 2003, Arthritis and rheumatism.
[29] W. Thomson,et al. IL-6 promoter polymorphism at position -174 modulates the phenotypic expression of polymyalgia rheumatica in biopsy-proven giant cell arteritis. , 2002, Clinical and experimental rheumatology.
[30] J. Fernandez-Solà,et al. A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant-cell arteritis. , 2002, Arthritis and rheumatism.
[31] A. Hajeer,et al. Visual Manifestations of Giant Cell Arteritis: Trends and Clinical Spectrum in 161 Patients , 2000, Medicine.
[32] E. Gromnica-ihle,et al. Color duplex ultrasonography in the diagnosis of temporal arteritis. , 1997, The New England journal of medicine.
[33] G. Hunder,et al. Tissue Cytokine Patterns in Patients with Polymyalgia Rheumatica and Giant Cell Arteritis , 1994, Annals of Internal Medicine.
[34] G. Hunder,et al. Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis. , 1993, Arthritis and rheumatism.
[35] L. A. Healey,et al. Polymyalgia rheumatica and giant cell arteritis. , 1984, The Western journal of medicine.
[36] P. Kieffer,et al. [Clinical and biological efficacy of tocilizumab in giant cell arteritis: report of three patients and literature review]. , 2014, La Revue de medecine interne.
[37] P. Kieffer,et al. Efficacité clinique et biologique du tocilizumab au cours de la maladie de Horton : à propos de trois observations et revue de la littérature , 2013 .
[38] A. Portier,et al. Production of interleukin 6 by granulomas of giant cell arteritis. , 1994, Human immunology.